Letermovir

證據等級: L5

預測適應症: 1 個

Letermovir: From CMV Prophylaxis to Vulvovaginal Candidiasis

One-Sentence Summary

Letermovir is an antiviral agent specifically developed for prophylaxis against cytomegalovirus (CMV) infection in hematopoietic stem cell transplant recipients. The TxGNN model predicts it may be effective for Vulvovaginal Candidiasis, yet zero clinical trials and zero publications currently support this direction — evidence sits at the lowest level (L5), and mechanistic analysis strongly suggests this is a knowledge graph topological false positive rather than a genuine pharmacological signal.

Quick Overview

Item	Content
Original Indication	CMV prophylaxis in hematopoietic stem cell transplant recipients
Predicted New Indication	Vulvovaginal Candidiasis
TxGNN Prediction Score	99.88%
Evidence Level	L5
Italy Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not formally available in this Evidence Pack. Based on known pharmacology, Letermovir selectively inhibits the CMV viral terminase complex (subunits UL51/UL56/UL89) — an enzyme the virus uses to cleave and package newly replicated DNA into virion capsids. This mechanism is exquisitely specific to human herpesvirus 5 (CMV) and has no documented activity against any fungal pathogen.

Vulvovaginal candidiasis is caused by Candida spp. (predominantly C. albicans), whose pathogenesis involves ergosterol biosynthesis and β-1,3-glucan cell wall synthesis — biochemical pathways entirely unrelated to viral DNA terminase enzymes. There is no established or plausible biological bridge between Letermovir's antiviral mechanism and antifungal activity.

The strikingly high TxGNN score (99.88%) almost certainly reflects a knowledge graph topological false positive: immunosuppressed hematopoietic stem cell transplant recipients receive Letermovir for CMV prophylaxis while simultaneously carrying elevated risk for opportunistic fungal infections, including candidiasis. This patient-level co-occurrence creates spurious node co-association in the knowledge graph — a statistical artifact, not a pharmacological relationship.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN prediction linking Letermovir to vulvovaginal candidiasis is assessed as a knowledge graph topological false positive with no mechanistic basis, no clinical trial support, and no literature evidence (Evidence Level L5). Pursuing this indication without any biological rationale would not be a responsible use of development resources.

To revisit this decision, the following would be needed:

In vitro data demonstrating any Letermovir activity against Candida species
A credible mechanistic hypothesis explaining how CMV terminase inhibition could produce antifungal effects
At minimum one preclinical study (animal model or cell-based) showing efficacy in a fungal infection setting
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.